Li N - Search Results

1

Development and Testing of a Mobile App for Pain Management Among Cancer Patients Discharged From Hospital Treatment: Randomized Controlled Trial.

Yang J, Weng L, Chen Z, Cai H, Lin X, Hu Z, Li N, Lin B, Zheng B, Zhuang Q, Du B, Zheng Z, Liu M. Yang J, et al. Among authors: li n. JMIR Mhealth Uhealth. 2019 May 29;7(5):e12542. doi: 10.2196/12542. JMIR Mhealth Uhealth. 2019. PMID: 31144672 Free PMC article. Clinical Trial.

2

Cost Effectiveness of Imatinib, Dasatinib, and Nilotinib as First-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia in China.

Li N, Zheng B, Cai HF, Yang J, Luo XF, Weng LZ, Zhan FM, Liu MB. Li N, et al. Clin Drug Investig. 2018 Jan;38(1):79-86. doi: 10.1007/s40261-017-0587-z. Clin Drug Investig. 2018. PMID: 29027641

3

Cost-effectiveness analysis of oral probiotics for the prevention of Clostridium difficile-associated diarrhoea in children and adolescents.

Li N, Zheng B, Cai HF, Chen YH, Qiu MQ, Liu MB. Li N, et al. J Hosp Infect. 2018 Aug;99(4):469-474. doi: 10.1016/j.jhin.2018.04.013. Epub 2018 Apr 17. J Hosp Infect. 2018. PMID: 29678466

4

From population to individuals: a new indicator for evaluating the appropriateness of clinical application of antibiotics.

Zheng B, Li N, Hu Z, Liu M. Zheng B, et al. Among authors: li n. BMC Pharmacol Toxicol. 2018 Sep 5;19(1):55. doi: 10.1186/s40360-018-0245-y. BMC Pharmacol Toxicol. 2018. PMID: 30185217 Free PMC article.

5

Cost-effectiveness analysis of UGT1A1*6/*28 genotyping for preventing FOLFIRI-induced severe neutropenia in Chinese colorectal cancer patients.

Wei X, Cai J, Sun H, Li N, Xu C, Zhang G, Sui Y, Zhuang J, Zheng B. Wei X, et al. Among authors: li n. Pharmacogenomics. 2019 Mar;20(4):241-249. doi: 10.2217/pgs-2018-0138. Epub 2019 Jan 10. Pharmacogenomics. 2019. PMID: 30628534

6

Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China.

Cai H, Zhang L, Li N, Chen S, Zheng B, Yang J, Weng L, Liu MB. Cai H, et al. Among authors: li n. Clin Ther. 2019 Feb;41(2):280-290. doi: 10.1016/j.clinthera.2018.12.007. Epub 2019 Jan 11. Clin Ther. 2019. PMID: 30639208

7

Cost-effectiveness of antiosteoporosis strategies for postmenopausal women with osteoporosis in China.

Li N, Zheng B, Liu M, Zhou H, Zhao L, Cai H, Huang J. Li N, et al. Menopause. 2019 Aug;26(8):906-914. doi: 10.1097/GME.0000000000001339. Menopause. 2019. PMID: 30994577

8

Cost-effectiveness analysis on binary/triple therapy on the basis of ixazomib or bortezomib for refractory or relapsed multiple myeloma.

Cai H, Zhang L, Li N, Zheng B, Liu M. Cai H, et al. Among authors: li n. Leuk Lymphoma. 2019 Dec;60(12):2951-2959. doi: 10.1080/10428194.2019.1620947. Epub 2019 Jun 4. Leuk Lymphoma. 2019. PMID: 31161831

9

Cost-Effectiveness Analysis Of Ceritinib And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer.

Liu M, Zhang L, Huang Q, Li N, Zheng B, Cai H. Liu M, et al. Among authors: li n. Cancer Manag Res. 2019 Oct 25;11:9195-9202. doi: 10.2147/CMAR.S223441. eCollection 2019. Cancer Manag Res. 2019. PMID: 31749634 Free PMC article.

10

Cost-Effectiveness Analysis Of Pembrolizumab In The Treatment Of Advanced Recurrent Metastatic Head And Neck Squamous Cell Carcinoma In China And The United States.

Liu M, Han S, Zheng B, Cai H, Yang J, Zhuang Q, Li N. Liu M, et al. Among authors: li n. Cancer Manag Res. 2019 Nov 11;11:9483-9493. doi: 10.2147/CMAR.S226243. eCollection 2019. Cancer Manag Res. 2019. PMID: 31814756 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

25,939 results

Search Page

Filters